Kyrgiou Maria, Athanasiou Antonios, Kalliala Ilkka E J, Paraskevaidi Maria, Mitra Anita, Martin-Hirsch Pierre Pl, Arbyn Marc, Bennett Phillip, Paraskevaidis Evangelos
Surgery and Cancer - West London Gynaecological Cancer Centre, Imperial College London - Queen Charlotte's & Chelsea, Hammersmith Hospital, Imperial NHS Healthcare Trust, Du Cane Road, London, UK, W12 0NN.
Cochrane Database Syst Rev. 2017 Nov 2;11(11):CD012847. doi: 10.1002/14651858.CD012847.
The mean age of women undergoing local treatment for pre-invasive cervical disease (cervical intra-epithelial neoplasia; CIN) or early cervical cancer (stage IA1) is around their 30s and similar to the age of women having their first child. Local cervical treatment has been correlated to adverse reproductive morbidity in a subsequent pregnancy, however, published studies and meta-analyses have reached contradictory conclusions.
To assess the effect of local cervical treatment for CIN and early cervical cancer on obstetric outcomes (after 24 weeks of gestation) and to correlate these to the cone depth and comparison group used.
We searched the following databases: Cochrane Central Register of Controlled Trials (CENTRAL; the Cochrane Library, 2017, Issue 5), MEDLINE (up to June week 4, 2017) and Embase (up to week 26, 2017). In an attempt to identify articles missed by the search or unpublished data, we contacted experts in the field and we handsearched the references of the retrieved articles and conference proceedings.
We included all studies reporting on obstetric outcomes (more than 24 weeks of gestation) in women with or without a previous local cervical treatment for any grade of CIN or early cervical cancer (stage IA1). Treatment included both excisional and ablative methods. We excluded studies that had no untreated reference population, reported outcomes in women who had undergone treatment during pregnancy or had a high-risk treated or comparison group, or both DATA COLLECTION AND ANALYSIS: We classified studies according to the type of treatment and the obstetric endpoint. Studies were classified according to method and obstetric endpoint. Pooled risk ratios (RR) and 95% confidence intervals (CIs) were calculated using a random-effects model and inverse variance. Inter-study heterogeneity was assessed with I statistics. We assessed maternal outcomes that included preterm birth (PTB) (spontaneous and threatened), preterm premature rupture of the membranes (pPROM), chorioamnionitis, mode of delivery, length of labour, induction of delivery, oxytocin use, haemorrhage, analgesia, cervical cerclage and cervical stenosis. The neonatal outcomes included low birth weight (LBW), neonatal intensive care unit (NICU) admission, stillbirth, perinatal mortality and Apgar scores.
We included 69 studies (6,357,823 pregnancies: 65,098 pregnancies of treated and 6,292,725 pregnancies of untreated women). Many of the studies included only small numbers of women, were of heterogenous design and in their majority retrospective and therefore at high risk of bias. Many outcomes were assessed to be of low or very low quality (GRADE assessment) and therefore results should be interpreted with caution. Women who had treatment were at increased overall risk of preterm birth (PTB) (less than 37 weeks) (10.7% versus 5.4%, RR 1.75, 95% CI 1.57 to 1.96, 59 studies, 5,242,917 participants, very low quality), severe (less than 32 to 34 weeks) (3.5% versus 1.4%, RR 2.25, 95% CI 1.79 to 2.82), 24 studies, 3,793,874 participants, very low quality), and extreme prematurity (less than 28 to 30 weeks) (1.0% versus 0.3%, (RR 2.23, 95% CI 1.55 to 3.22, 8 studies, 3,910,629 participants, very low quality), as compared to women who had no treatment.The risk of overall prematurity was higher for excisional (excision versus no treatment: 11.2% versus 5.5%, RR 1.87, 95% CI 1.64 to 2.12, 53 studies, 4,599,416 participants) than ablative (ablation versus no treatment: 7.7% versus 4.6%, RR 1.35, 95% CI 1.20 to 1.52, 14 studies, 602,370 participants) treatments and the effect was higher for more radical excisional techniques (less than 37 weeks: cold knife conisation (CKC) (RR 2.70, 95% CI 2.14 to 3.40, 12 studies, 39,102 participants), laser conisation (LC) (RR 2.11, 95% CI 1.26 to 3.54, 9 studies, 1509 participants), large loop excision of the transformation zone (LLETZ) (RR 1.58, 95% CI 1.37 to 1.81, 25 studies, 1,445,104 participants). Repeat treatment multiplied the risk of overall prematurity (repeat versus no treatment: 13.2% versus 4.1%, RR 3.78, 95% CI 2.65 to 5.39, 11 studies, 1,317,284 participants, very low quality). The risk of overall prematurity increased with increasing cone depth (less than 10 mm to 12 mm versus no treatment: 7.1% versus 3.4%, RR 1.54, 95% CI 1.09 to 2.18, 8 studies, 550,929 participants, very low quality; more than 10 mm to 12 mm versus no treatment: 9.8% versus 3.4%, RR 1.93, 95% CI 1.62 to 2.31, 8 studies, 552,711 participants, low quality; more than 15 mm to 17 mm versus no treatment: 10.1 versus 3.4%, RR 2.77, 95% CI 1.95 to 3.93, 4 studies, 544,986 participants, very low quality; 20 mm or more versus no treatment: 10.2% versus 3.4%, RR 4.91, 95% CI 2.06 to 11.68, 3 studies, 543,750 participants, very low quality). The comparison group affected the magnitude of effect that was higher for external, followed by internal comparators and ultimately women with disease, but no treatment. Untreated women with disease and the pre-treatment pregnancies of the women who were treated subsequently had higher risk of overall prematurity than the general population (5.9% versus 5.6%, RR 1.24, 95% CI 1.14 to 1.34, 15 studies, 4,357,998 participants, very low quality).pPROM (6.1% versus 3.4%, RR 2.36, 95% CI 1.76 to 3.17, 21 studies, 477,011 participants, very low quality), low birth weight (7.9% versus 3.7%, RR 1.81, 95% CI 1.58 to 2.07, 30 studies, 1,348,206 participants, very low quality), NICU admission rate (12.6% versus 8.9%, RR 1.45, 95% CI 1.16 to 1.81, 8 studies, 2557 participants, low quality) and perinatal mortality (0.9% versus 0.7%, RR 1.51, 95% CI 1.13 to 2.03, 23 studies, 1,659,433 participants, low quality) were also increased after treatment.
AUTHORS' CONCLUSIONS: Women with CIN have a higher baseline risk for prematurity. Excisional and ablative treatment appears to further increases that risk. The frequency and severity of adverse sequelae increases with increasing cone depth and is higher for excision than it is for ablation. However, the results should be interpreted with caution as they were based on low or very low quality (GRADE assessment) observational studies, most of which were retrospective.
接受宫颈上皮内瘤变(CIN)或早期宫颈癌(IA1期)局部治疗的女性平均年龄在30岁左右,与首次生育的女性年龄相近。宫颈局部治疗与后续妊娠的不良生殖结局相关,然而,已发表的研究和荟萃分析得出了相互矛盾的结论。
评估CIN和早期宫颈癌的宫颈局部治疗对产科结局(妊娠24周后)的影响,并将这些影响与锥切深度和所用的对照组进行关联分析。
我们检索了以下数据库:Cochrane对照试验中心注册库(CENTRAL;Cochrane图书馆,2017年第5期)、MEDLINE(截至2017年6月第4周)和Embase(截至2017年第26周)。为了识别检索遗漏的文章或未发表的数据,我们联系了该领域的专家,并手工检索了检索到的文章的参考文献和会议论文集。
我们纳入了所有报告有或没有接受过任何级别的CIN或早期宫颈癌(IA1期)宫颈局部治疗的女性产科结局(妊娠超过24周)的研究。治疗方法包括切除和消融。我们排除了没有未治疗对照人群的研究、报告了孕期接受治疗的女性或有高风险治疗组或对照组或两者皆有的女性的结局的研究。
我们根据治疗类型和产科终点对研究进行分类。研究根据方法和产科终点进行分类。使用随机效应模型和逆方差计算合并风险比(RR)和95%置信区间(CI)。用I统计量评估研究间的异质性。我们评估了孕产妇结局,包括早产(PTB)(自发早产和先兆早产)、胎膜早破(pPROM)、绒毛膜羊膜炎、分娩方式、产程长度、引产、催产素使用、出血、镇痛、宫颈环扎和宫颈狭窄。新生儿结局包括低出生体重(LBW)、新生儿重症监护病房(NICU)入院、死产、围产期死亡率和阿氏评分。
我们纳入了69项研究(6357823例妊娠:65098例接受治疗的妊娠和6292725例未接受治疗的女性妊娠)。许多研究仅纳入了少量女性,设计各异,且大多数为回顾性研究,因此存在较高的偏倚风险。许多结局被评估为低质量或极低质量(GRADE评估),因此对结果的解释应谨慎。与未接受治疗的女性相比,接受治疗的女性早产(PTB)(小于37周)的总体风险增加(10.7%对5.4%,RR 1.75,95%CI 1.57至1.96,59项研究,5242917名参与者,极低质量)、严重早产(小于32至34周)(3.5%对1.4%,RR 2.25,95%CI 1.79至2.82,24项研究,3793874名参与者,极低质量)和极早早产(小于28至30周)(1.0%对0.3%,RR 2.23,95%CI 1.55至3.22,8项研究,3910629名参与者,极低质量)。切除治疗(切除与未治疗:11.2%对5.5%,RR 1.87,95%CI 1.64至2.12,53项研究,4599416名参与者)的总体早产风险高于消融治疗(消融与未治疗:7.7%对4.6%,RR 1.35,95%CI 1.20至1.52,14项研究,602370名参与者),更激进的切除技术的影响更高(小于37周:冷刀锥切术(CKC)(RR 2.70,95%CI 2.14至3.40,12项研究,39102名参与者)、激光锥切术(LC)(RR 2.11,95%CI 1.26至3.54,9项研究,1509名参与者)、转化区大环形切除术(LLETZ)(RR 1.58,95%CI 1.37至1.81,25项研究,1445104名参与者))。重复治疗使总体早产风险成倍增加(重复治疗与未治疗:13.2%对4.1%,RR 3.78,95%CI 2.65至5.39,11项研究,1317284名参与者,极低质量)。总体早产风险随着锥切深度的增加而增加(小于10mm至12mm与未治疗:7.1%对3.4%,RR 1.54,95%CI 1.09至2.18,8项研究,550929名参与者,极低质量;大于10mm至12mm与未治疗:9.8%对3.4%,RR 1.93,95%CI 1.62至2.31,8项研究,552711名参与者,低质量;大于15mm至17mm与未治疗:10.1%对3.4%,RR 2.77,95%CI 1.95至3.93,4项研究,544986名参与者,极低质量;20mm或以上与未治疗:10.2%对3.4%,RR 4.91,95%CI 2.06至11.68,3项研究,543750名参与者,极低质量)。对照组影响效应大小,外部对照组的效应更高,其次是内部对照组,最终是患有疾病但未接受治疗的女性。患有疾病但未接受治疗的女性以及随后接受治疗的女性的治疗前妊娠的总体早产风险高于一般人群(5.9%对5.6%,RR 1.24,95%CI 1.14至1.34,15项研究,4357998名参与者,极低质量)。治疗后胎膜早破(6.1%对3.4%,RR 2.36,95%CI 1.76至3.17,21项研究,477011名参与者,极低质量)、低出生体重(7.9%对3.7%,RR 1.81,95%CI 1.58至2.07,30项研究,1348206名参与者,极低质量)、NICU入院率(12.6%对8.9%,RR 1.45,95%CI 1.16至1.81,8项研究,2557名参与者,低质量)和围产期死亡率(0.9%对0.7%,RR 1.51,95%CI 1.13至2.03,23项研究,1659433名参与者,低质量)也有所增加。
CIN女性早产的基线风险较高。切除和消融治疗似乎会进一步增加这种风险。不良后遗症的频率和严重程度随着锥切深度的增加而增加,切除治疗比消融治疗更高。然而,由于这些结果基于低质量或极低质量(GRADE评估)的观察性研究,其中大多数是回顾性研究,因此对结果的解释应谨慎。